RxDoctor Payments Data

Eric Goldberg, MD

Gastroenterology · Baltimore, MDNPI 1083664312

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (58.5%), consulting fees and education — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Boston Scientific at 31.3% of the total. Reporting peaked in 2020 at $34,433 and has fallen 63.4% since, to $12,592 in 2025. Among gastroenterology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$109,883in general payments, 2019–2025

Across 233 payments — averaging $471.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$34K
  • Covidien LP$32K
  • Medtronic$27K
  • Olympus Corporation Of The Americas$7K
  • Ambu A/s$7K
  • Olympus Corporation$923
  • plus $1K from 8 others

What the payments were for

  • Consulting fees$31,85629%
  • Speaking & faculty fees$64,23058%
  • Travel & lodging$1,3461%
  • Food & beverage$5,0765%
  • Education$7,3607%
  • Gifts$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$109,883 in reported general payments places this provider in the 95th percentile of 455 gastroenterology providers in Maryland.

See all gastroenterology providers in Maryland

Medicare billing

Part B allowed, 2024
$100,582
Medicare patients
283
Services billed
585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide22$39,738
ClenpiqSod Picosulf/Mag Ox/Citric Ac13$2,230
Pantoprazole Sodium110$1,743
Ondansetron OdtOndansetron49$1,209
Esomeprazole Magnesium36$1,179
Omeprazole36$791
Colestipol Hcl13$760
Sucralfate14$413
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl30$394
Alprazolam17$381
Amitriptyline Hcl31$301
Famotidine35$231
Oxycodone Hcl18$196
Metoclopramide Hcl27$195
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl12$181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$151$39,73822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 455 gastroenterology providers in Maryland.

Other gastroenterology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →